Biomedicines | Free Full-Text | Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy - ScienceDirect
GeparNUEVO: durvalumab plus neoadjuvant chemotherapy in TNBC demonstrates long-term clinical benefit - Onco Americas
IJMS | Free Full-Text | Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
Durvalumab (Imfinzi) Drug Information
Frontiers | What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response - BJMO
Durvalumab Side Effects: Common, Severe, Long Term
Treatment patterns and long‐term survival outcomes for patients with stage III non‐small cell lung cancer: A retrospective study - Kumari - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
Education & Resources for Oncology Nurses – IMFINZI® (durvalumab)
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy - ScienceDirect
Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer | ONS
Imfinzi Duravalumab Injection, 500 mg/10 mL at Rs 8999/box in New Delhi | ID: 2853132773630
Side-effects of Short Term and Long Term Glucocortcoid Use | Download Table
The ocular side effects of emerging oncology meds
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management | Cleveland Clinic Journal of Medicine
Immune-checkpoint inhibitors: long-term implications of toxicity | Nature Reviews Clinical Oncology
Current Oncology | Free Full-Text | Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study
Full article: Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer
Immunotherapy: Pushing the Frontier of Cancer Medicine | AACR Cancer Progress Report
